Induction of human macrophage vascular endothelial growth factor and intercellular adhesion molecule-1 by Ureaplasma...

Area of Science:

• Neonatal Medicine
• Pulmonary Medicine
• Microbiology

Background:

• Chronic lung disease (CLD) is a significant complication in premature infants.
• The exact causes of CLD are complex, with infection and inflammation playing key roles.
• The role of Ureaplasma urealyticum in CLD pathogenesis is debated, though steroids show some benefit.

Purpose of the Study:

• To investigate if Ureaplasma urealyticum stimulates macrophages to produce vascular endothelial growth factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1) in vitro.
• To determine the association of these factors with early and late lung pathology in CLD.
• To examine the effects of dexamethasone and budesonide on these U. urealyticum-induced responses.

Main Methods:

• Ureaplasma urealyticum antigen was used to stimulate human macrophages (THP-1 cell line).
• VEGF and soluble ICAM-1 production were measured using ELISA.
• Cell surface ICAM-1 expression was assessed by flow cytometry.
• mRNA expression of VEGF and ICAM-1 was analyzed via RT-PCR.
• TNF-alpha neutralization was performed using an anti-TNF-alpha antibody.

Main Results:

• U. urealyticum antigen dose-dependently stimulated macrophages to produce VEGF and soluble ICAM-1 (p < 0.05).
• Cell surface ICAM-1 expression increased upon U. urealyticum stimulation, an effect attenuated by budesonide and dexamethasone (p < 0.05).
• mRNA expression of VEGF and ICAM-1 was induced by U. urealyticum and inhibited by steroids (p < 0.05).
• Neutralizing TNF-alpha reduced ICAM-1 expression by 85.5%.

Conclusions:

• Ureaplasma urealyticum may contribute to the development of CLD in premature infants.
• U. urealyticum-induced VEGF and ICAM-1 production are potential mechanisms in CLD pathogenesis.
• Steroids demonstrate an inhibitory effect on these inflammatory pathways, suggesting a therapeutic role.